Author / Speaker: Bendicksen, Liam

A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available in the EU, UK, and US

March 6, 2026

Seeking a Better Paper Trail of Federal Research Funding

March 6, 2026

Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention

March 6, 2026

Op-Ed: This Gene Therapy May Not Work. So Why Did the FDA Fully Approve It?

March 6, 2026

Federal Enforcement of Pharmaceutical Fraud Under the False Claims Act, 2006-2022

March 6, 2026

Spending on Targeted Therapies for Duchenne Muscular Dystrophy

March 6, 2026

FDA and Chevron Deference: A Case Review

March 6, 2026

Identifying Therapeutic Alternatives in Medicare Drug Price Negotiation: The Case of Etanercept

March 6, 2026

The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence

March 6, 2026

Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the US

March 6, 2026

Protecting Medicare’s Discretion to Say No to Unproven Therapies

March 6, 2026

Eroding Judicial Deference to the FDA—Consequences for Public Health

March 6, 2026